13th Edition of Global Conference on Pharmaceutics and Novel Drug Delivery Systems

Event type: Pharmaceutical Sciences, Drug Delivery, Formulation Development, Biopharma Research, Clinical Translation, Contract Services, Scientific Conference

Date: Please confirm the current edition dates on the official event website before campaign execution.

Venue: Please confirm the host city and venue on the official event website, as this conference series may rotate internationally or run in hybrid formats depending on the edition.

Estimated attendance: Typically a mid-sized to large scientific conference audience, often in the range of 300 to 1,500+ total participants depending on location, partnering institutions, scientific committee strength, and hybrid participation levels.

Event overview

The 13th Edition of Global Conference on Pharmaceutics and Novel Drug Delivery Systems is best understood as a specialized pharmaceutical and life sciences conference focused on formulation science, advanced delivery platforms, bioavailability enhancement, controlled release, nanomedicine, biologics delivery, regulatory development, clinical translation, and manufacturing innovation. Unlike broad healthcare expos that attract general hospital traffic, this event is much more research-driven and innovation-oriented. The most valuable professional audience usually includes formulation scientists, pharmaceutical R&D leaders, drug delivery technology specialists, outsourcing partners, CDMOs, excipient suppliers, analytical service providers, packaging and containment experts, device-development teams, and academic researchers working on translational medicine.

From a commercial perspective, this is a strong fit for companies offering formulation technologies, drug delivery platforms, excipients, encapsulation systems, analytical testing, bioavailability enhancement solutions, laboratory instruments, fill-finish systems, clinical manufacturing support, regulatory consulting, and pharmaceutical development services. We would not position this event as a mass-market medical gathering; we would position it as a targeted scientific and business environment where highly relevant pharmaceutical decision-makers and technical influencers participate.

1️⃣ Who attends: buyers / attendees

The attendee base at this conference is usually highly specialized. The audience is not limited to one buyer type, because pharmaceutics and drug delivery decisions involve both scientific and commercial stakeholders. In most editions, we should expect a mix of the following groups:

• Pharmaceutical company R&D teams
• Formulation development scientists
• Drug delivery platform researchers
• Preclinical and translational medicine specialists
• Biopharma development managers
• Clinical development and CMC stakeholders
• Contract development and manufacturing organizations
• Excipients and specialty ingredients suppliers
• Analytical testing and laboratory service providers
• Medical device and combination-product teams
• Academics and principal investigators in pharmaceutics
• Regulatory affairs and quality professionals
• Business development managers from pharma service providers
• Innovation, licensing, and alliance-management leaders
• Investors and strategy professionals focused on drug delivery technologies

The strongest buyer profiles are usually found in pharmaceutical manufacturers, biotechnology companies, CDMOs, drug delivery technology firms, excipient suppliers, laboratory and analytical partners, and specialized equipment companies. Academic participation is often strong as well, but for commercial targeting, we would focus first on industry attendees, sponsors, solution providers, translational research leaders, and scientific heads with budget influence or technology evaluation authority.

2️⃣ Where the show is happening + attendee geographic origin

This conference is positioned as a global meeting, which means location matters, but the attendee mix is usually broader than the host city itself. Since the exact venue may vary by edition, we recommend verifying the official event page before final outreach. That said, the attendee origin for a conference in this category generally includes:

• Host-country pharmaceutical and biotech companies
• Regional life sciences clusters from the surrounding geography
• National research universities and pharmaceutical institutes
• International speakers and scientific advisory members
• Global pharma service providers and technology vendors
• Cross-border participants from Europe, North America, Asia-Pacific, and the Middle East

If the event is held in Europe, we should expect strong participation from the UK, Germany, Switzerland, France, Italy, the Netherlands, Belgium, Ireland, Spain, and Nordic life sciences hubs. If the conference is hosted in North America, we should expect stronger representation from the United States and Canada, along with selected global pharmaceutical groups. If it is run in hybrid mode, the practical geographic reach expands significantly, especially for academic speakers and research professionals.

3️⃣ Audience reach

Reach type: Global, with strong regional concentration based on host location

This is not a purely local or city-level event. It is designed for an international scientific and pharmaceutical audience. However, actual buyer density typically follows a three-layer pattern:

1. Local and regional layer: Companies, universities, hospitals, and laboratories near the host venue
2. National layer: Country-wide pharmaceutical manufacturers, biotech firms, and research institutions
3. Global layer: Multinational pharma, international CDMOs, scientific speakers, and advanced technology vendors

In practical terms, we would classify this conference as global in positioning, international in participation, and high-value niche in buyer relevance. It is especially useful where the client offering serves formulation science, drug development, biologics delivery, specialty materials, device integration, or technical outsourcing.

4️⃣ Sample buyer company names + websites

Below is a sample list of strong buyer-fit organizations that align well with a pharmaceutics and novel drug delivery conference environment. These are the kinds of organizations we would prioritize first because they are active in formulation science, oral solid dose innovation, biologics delivery, CDMO services, analytical support, excipients, or advanced therapeutic development.

Top sample accounts to prioritize first: Pfizer, Novartis, Roche, AstraZeneca, Lonza, Catalent, Evonik Health Care, BASF Pharma Solutions, Colorcon, and West Pharmaceutical Services. These provide a strong mix of pharmaceutical innovators, development partners, delivery-material suppliers, and technical solution providers.

5️⃣ Job profiles, industries & event type

Best job profiles to target

• Head of Formulation Development
• Director of Pharmaceutical Development
• Director of Drug Delivery
• Senior Scientist, Pharmaceutics
• Principal Scientist, Formulation Sciences
• Vice President, CMC
• Associate Director, Drug Product Development
• Director, Technical Operations
• Head of Preformulation
• Director, Analytical Development
• Director, Biopharmaceutics
• Director, External Innovation
• Business Development Director, CDMO Services
• Strategic Partnerships Manager
• Head of Product Development
• Director, Regulatory CMC
• Medical Device Development Manager
• Director, Innovation Programs
• Technical Sales Director, Pharma Solutions
• Global Marketing Manager, Pharmaceutical Technologies

Recommended industry filters

• Pharmaceuticals
• Biotechnology
• Medical Devices
• Hospital & Health Care
• Research
• Chemicals
• Nanotechnology
• Higher Education
• Education Management
• Information Technology & Services
• Mechanical or Industrial Engineering
• Packaging & Containers

Best-fit event category

This is a scientific and business-facing pharmaceutical development conference, especially relevant for pharmaceutics, delivery systems, formulation innovation, analytical support, manufacturing services, excipients, clinical translation, and therapeutic commercialization.

6️⃣ Estimated attendance / expected footfall

Because this event belongs to a specialized scientific conference category rather than a giant expo category, overall attendance is usually more concentrated and quality-driven. A realistic estimate for this type of conference is 300 to 1,500+ participants depending on:

• Host city attractiveness and travel ease
• Strength of academic and scientific committee
• Level of sponsorship and industry support
• Number of colocated tracks and partner sessions
• Virtual or hybrid participation availability

The key point is that total footfall may be lower than mass healthcare conventions, but buyer relevance is often significantly higher. In this type of event, the commercial value comes from specialized scientific decision-makers, not from sheer crowd size.

7️⃣ Key focus areas & buyer engagement

Key focus areas we should expect

• Novel drug delivery systems
• Nanoparticles and nanomedicine
• Lipid-based and polymer-based formulations
• Oral controlled release and modified release technologies
• Injectable and parenteral delivery systems
• Biologics and peptide delivery
• Transdermal, mucosal, nasal, pulmonary, and ocular delivery
• Targeted therapeutics and precision delivery
• Bioavailability enhancement and solubility improvement
• CMC development and scale-up
• Excipient innovation and material science
• Analytical characterization and stability testing
• Regulatory pathways and quality considerations
• Clinical translation and commercialization strategy
• Combination products and device-enabled delivery

How buyer engagement typically happens

Engagement at this conference is usually driven less by broad exhibition traffic and more by technical relevance. Buyers and decision-makers are most responsive when messaging is connected to scientific outcomes, development efficiency, formulation complexity, manufacturability, compliance, and speed to clinic or market.

The best positioning angles usually include:

• Improving formulation performance
• Reducing development risk
• Enhancing bioavailability or targeted delivery
• Supporting complex modalities and difficult molecules
• Accelerating scale-up and transfer to manufacturing
• Strengthening regulatory readiness and analytical confidence
• Enabling differentiated product lifecycle strategies

8️⃣ Client-product fit note

To refine the final buyer strategy properly, we should first review the client website and product offering. Once we have the website, we can map the event much more accurately and identify the strongest-fit companies, titles, and industry clusters based on what the client actually sells.

Please share the client website, and we will review it and confirm:

• Which attendee segments are the best fit
• Which buyer companies should be prioritized first
• Which job titles have the highest likelihood of engagement
• Which industry filters should be used most aggressively
• Whether the event is better for enterprise pharma, CDMOs, excipient companies, device firms, or academic-commercial hybrid outreach

Examples of product-fit direction

• If the client sells CDMO or contract development services, we should prioritize pharmaceutical companies, biotech firms, virtual biotechs, and translational development teams.
• If the client sells excipients, polymers, or specialty materials, we should prioritize formulation scientists, oral dosage teams, controlled-release specialists, and technical procurement stakeholders.
• If the client sells analytical instruments or lab services, we should target analytical development, stability, quality, and pharmaceutical sciences groups.
• If the client sells drug delivery platforms, we should target innovation, preformulation, device development, biologics formulation, and advanced therapeutics teams.
• If the client sells regulatory, CMC, or quality consulting, we should prioritize development leadership, technical operations, and program-management stakeholders.

9️⃣ Final recommendation

Yes, this is a strong event for highly targeted pharmaceutical and life sciences outreach, especially when the client product is scientifically relevant to formulation, delivery, manufacturing, analytical support, or pharmaceutical development strategy.

The biggest strength of this conference is not mass scale. Its value is the concentration of relevant specialists from pharmaceutics, novel delivery, biopharma development, and outsourcing ecosystems. That means the event is especially useful when we want quality over volume.

Best buyer segments to prioritize

• Pharmaceutical development leaders
• Formulation scientists and pharmaceutics heads
• Drug delivery innovation teams
• CDMO business development leaders
• Excipients and specialty ingredient companies
• Analytical and laboratory solution providers
• Medical device and injectable systems companies
• Biotech translational and CMC teams

Overall quality rating for B2B relevance: 8.5/10

We rate it highly because the audience is niche, scientifically aligned, and commercially meaningful for pharmaceutical, biotech, drug delivery, excipients, CDMO, and technical solutions clients. The only caution is that success depends on matching the event with the right client product category. Once we review the client website, we can sharpen the target list and identify the most valuable buyer profiles with much greater precision.